Infection Control in the ICU Environment

1. Scope and Magnitude of Nosocomial ICU Infections U.S. Perspective:.- 2. Scope xand Magnitude of Nosocomial ICU Infections  European Perspective:.- 3. Vancomycin-Resistant Enterococci: A Threat for the ICU? U.S. Perspective:.- 4. Vancomycin-Resisitant Enterococci in Europe: A Changing Epidemiology? European Perspective:.- 5. Methicillin-Resistant Staphylococcus Aureus: Is Control Necessary? U.S. Perspective:.- 6. Acinetobacter: Epidemiology and Control  U.S. Perspective:.- 7. Acinetobacter: Epidemiology and Control  European Perspective:.- 8. Fungal Infections: The Role of Prophylactic and Empiric Antifungal Therapy in ICU Patients U.S. Perspective:.- 9. Fungal Infections: The Role of Prophylaxis and Empiric Therapy in ICU Patients European Perspective:.- 10. Newer Approaches to Preventing Vascular Catheter-Related Sepsis  U.S. Perspective:.- 11. Newer Approaches to Preventing Intravascular Device-Related Bloodstream Infections European Perspective:.- 12. Is Prevention of Ventilator-Associated Pneumonia Cost Effective? North American Perspective:.- 13. Ventilator-Associated Pneumonia: Is Prevention Cost Effective? European Perspective:.- 14. Cross-Colonization in Intensive Care Units: Fact or Fiction? U.S. Perspective:.- 15. Cross-Colonization: Fact or Fiction? European Perspective:.- 16. Conventional Infection Control Measures: Value or Ritual? U.S. Perspective:.- 17. Conventional Infection Control Measures: Value or Ritual? European Perspective:.- 18. Modeling of Antibiotic Resistance in the ICU  U.S. Perspective:.- 19. Mathematical Models in the ICU: Dynamics, Infection Control and Antibiotic Resistance European Perspective:.